Loading stock data…
Neumora Therapeutics, Inc. (NMRA)
$1.49-0.07 (-4.49%)
Market ClosedLast close Jul 24
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neumora Therapeutics, Inc. in the Healthcare sector is trading at $1.49 with a market capitalization of $322M. Wall Street consensus targets $6.28 (8 analysts), implying a +321.6% move over the next 12 months. The stock is currently 59% below its 52-week high of $3.65, remaining 31.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +321.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 35) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$52.86M↑ | -$58.48M↓ | -$57.70M↓ | -$54.04M↑ | -$70.94M |
| Net Income | -$53.46M↑ | -$59.45M↓ | -$56.76M↓ | -$52.73M↑ | -$67.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$322.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-314.65%
Volume
Today's trading volume
665,726
Recent News
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
Neumora Therapeutics is back in focus after analysts cut their fair value estimate from US$8.91 to US$6.53 per share, a reduction of about 27% that resets expectations around the stock. Much of this shift tracks recent commentary on the decision to discontinue navacaprant, remove associated costs, and place more weight on the earlier stage pipeline, which bullish and bearish voices interpret very differently. As you read on, you will see how these updated targets fit into the evolving...
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is among the best get rich quick stocks to buy right now. On June 18, Mizuho lowered the price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $4, down from $6. This came after the company’s negative Phase 3 KOASTAL-2 and -3 study outcomes. The firm has now removed navacaprant for depression from […]
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list. TheFly reported on May 28 that Clear Street maintained a Buy rating and a $45 price target for LBRX. The firm stated that […]
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment being tested in patients with major depressive disorder. On May 7, Neumora said two late-stage studies, KOASTAL-2 and KOASTAL-3, were fully enrolled in the first quarter of 2026, […]
Three pivotal MDD trial failures for Neumora lead to staffing cuts
The KOASTAL 2 and KOASTAL 3 trials also failed to meet their endpoints, with Neumora now culling development of the MDD candidate